good and afternoon Linnell, you, Thank everyone.
role and those our transition you new For past a member and the of for January. to and Brown, Board introduce XX Directors in haven't Chairman opportunity March myself. CEO the of year My had iCAD. announcement, Dana is into I’m I I've been meet, leadership name to I the for wanted President per the of iCAD’s stepped
and including for Officer Business Software. Development was for Marketing first to of background and in member in iCAD career point ERP of the wanted XX founding why and I as technology at few multiple Chief a qualified media the providers. essentially to successful my MetaSolv I about internet MetaSolv to take lead ventures, years spent telecom, industry time. and you moments I'm uniquely tell Co-Founder my this a
and Telco became a model, many technology choosing players we while time, the at [ph]. to against focus a Lucent innovative had EY like entities one we disruptive, of killer, implementation projects. At $XX consistently who time million our unique my with of During for partnering time, a in had larger point our efforts the on including the tenure backlog for category building business winning deals services,
development was for partner grow our getting we to With than acquisition rigor, responsible I markets footprint competition. our and options to business us evaluated an strategy, geographies. strategy. implemented across ways faster bi-builder We continuously technology, our to enabling and aggressive market accelerate
the originally platform the We developed for mainframe environment.
Co-Founder suite. later ported Oracle of as I'm Oracle it built the and it Now, to redesigned subsequently later was and be largest the is still ever company was it server to and SaaS. took dating myself on the by really client acquired systems and public, My and it enterprise one I
Management Ipsum of it CEO Performance and Network became by I which MetaSolv, company After was acquired early was its credited route Networks, Software with stages. pioneering in a technology, analytics Cisco
new old, unlikely Chief partnership XXX most Cloud. a tech the Way billion Salesforce, build a of Way, years cloud $X from between and I global Officer to to its architected world's in Philanthropy old, XX non-profit, I turnaround until I a company, went XX the an partnership delivery non-profit Worldwide first innovative called Digital co-development ventures year be joined content the United the sector. when a year and sector year made team other and to mobile eight as United a ago on tech on space, shift running,
talent, reputation greater put and action. in their values to and each retaining attracting and endeavors, impact. platform reach delivering engaging a into that It empowers by top company's philanthropic extends employees brand its customers It's corporations and enhancing awareness,
has XX the world's more programs health invested Vice outreach, Officer more than breaking for organization. Most $X.X Komen and in community Susan than Senior and Strategy breast Chief in recently, a Komen, President, advocacy countries. billion research, I served G. breast Operations cancer ground as cancer leading
Health, gathered leading and efforts the engagement guide among patient other MyKomen our Komen, care experts, breast first transformation, end-to-end access in strategic aid, At to the researcher journey initiatives as I platform, our designed turnaround team with to patients create resources to and and through as deliveries cancer well determinants led and risk of from storing research patient well EMR, such EHR data, non-digital effort interventions, the ranging as ShareForCures, as documentation as cancer health genomic first powered diagnoses from including care information profiles, health, registry status, and breast of all data. digital
I've through streams. done product business strategy I've underlying be leveraged sustainable. through and not have revenue that. seismic and sizable simultaneously platforms but ways I've a create changing master turnarounds, doing and category that's business thriving challenging and models, and partners and for leader of while trite, been from teams summarize, been the there the companies, cost products in scale, reduction licensing led to To built measures, to diversifying and I've shifts ecosystem and models, up. responsible implementing ground become
for our our talented honored be and And growth. to to lives our alongside Cancer most pervasive world's future stakeholders. the Board, vision company. experience company and my position uniquely this leverage patients personalized prepared expertise incredible this creating and to for now I'm AI of partners, committed suite be I'm Solutions, and clients around Detection team, our the Working leading shareholders our world to to upholding changing for and I'm value
enough So my background. about
and financial Let's our update. business dive into
strategy Xoft business. Therefore we is options exploring business great competencies for potential, focus around on core strategic the both, lines solely and Detection and Therapy recently While have opportunity need AI. company and to we the be of market and believe announced our the detection our
potential that patients impact remain and them to of positively providers care lives the scale. a cancer Xoft for the has We confident technology the the global who on
of accessibility focus that transition, options and the this its want we accelerate we to growth. As through and technology explore provide this to move could time of strategic more synergies
increase. these by explore help Retaining these options. driven was banks strategic banks us relationship two We've based two to hired inbound
we of and that costs explore for line operational overhead we these reduced business. As opportunities,
We base, of annualized installed resulting as operations essential sales, to $X.X in servicing million. an have expenses supporting to as new on our in streamlined existing focus what's and well decrease
Moving and we worldwide, leading we the giving the detection cancers to women believe and cancer of among cancer outcomes detect opportunity common in in diagnosis of deaths technology, early a individuals and for in and to detection U.S. transforming quality journey most is is more the patient business, early With the early, saved. the second detection in our of iCAD’s ability battle cause the have positive live care. more women side part the the key cancer cancer against Breast
license it and platform products recurring grow over business more previous important for customers’ curve, us on-premise company, in of model from our customers to is meet a a and time by ensures change platform. technology in more stream on an based license of is model the revenue and leading and needs technology mentioned calls, subscription transition that services driven important can to our a business edge cloud a invest on change our As the future. based our sustainable to and adoption technology as This SaaS steady more perpetual quickly or enable the now
method scale and customers quickly associated to SaaS implementations more models. outlays for adopt, the with upfront customers Combining technologies costly easily new the and an with costs. with payment leverage functionality to our of enable deployment without lower accelerated of deploy subscription method capital offers traditional significantly way SaaS
While curve subscription this stages small. our demand we're continues adoption remains model, to still overall of early from be in the of promising licenses for the percentage the and revenue
as this becomes on hear it overall more our of percentage metric from us You'll more significant a revenue.
making have runway we business. the and further earnings As while cost and streamline cost business to announcement, change focused changes. important to we're a noted creating in long and we to on our broad continue run reduction a needed us, for the base. recalibrate reset year measures implemented and call It's We're our align already
the recently million have cash reduced several which $X.X reduced changes $X.X million. to $X.X to to analyzed expenses We million has $X.X and annualized million by been made dollars, burn operations,
and projecting model without the needed to strategic We of cash needing a business, changes capital. the return together exploring raise our to now business before profitability successfully result, for As believe we're additional be runway the end us with flow navigate to options give transition positive to these therapy XXXX.
to transitioning a platform. I just model about subscription moving business clear want SaaS to isn't our also be that
opportunities We growth assessments going are with our range offerings going through personalized like to powered a other solutions. and working patients, elective a such rigorous risk and of as process a DPT to access predictive digital thoughtful partners, to clinical evaluate with care platform, scoring new direct industry,
their in get pursuing breasts, looking as covered, medical and incurred save with We're thousands reimbursement stage assessments diagnoses late courses for in of of detection can early AI risk payer with strategies dollars dense women screenings treatment. at to particularly expenses read and
on utilizing they AI services large looking supporting programs and health platform our health disparities to address other tackling And get front to we're We're initiatives campus. on women's advocacy need. breast care health and the partnering to based all cancers aid screening with employers, provide at organizations lines mobile the We're of with cloud at access help powered AI looking expanding to modalities. patient women
initiatives. risk existing into these to breast of strong integrate Google mitigate agreement commercialization technology us our new strategic have partnerships its can into our AI Partnerships We with and artificial help expanding development intelligence the that Health like suite.
practice, to as and first has as of breast commercial introduce women discussed, expand our into AI Health imaging well mammography, clinical to to our positioned for leading As this technology and solutions it the cancer AI is worldwide. is breast previously partnership improve to Google providers access market millions into its entered
of services the the largest our Like independent U.S. breast Mammography, provider diagnostic with Solis screening partnership and in
AI is new the called country the Mammo+Plus. Solis program first offer profound in with to direct-to-patient the risk
with could disease development at data risk. using mammogram. Additionally, application risk A for millions on collaboration new using define obtained and identify from cardiovascular a Solis, heart commercial announced quarter their we that agreement last focused mammography of to new women
care, being the in this among potential new in annually. the market, unmet disease heart need to a million U.S., penetrate the address the are offers given screened sizeable also collaboration significant patient killer only to U.S. a that women number women in not XX one but approximately With
of remiss I with existing leverage didn't companies Rad with if Siemens, Partners. relationship partnerships I developing technology and the further lastly, ability GE would are course top like our mention And be and to medical
competitive revenue long a preserving diversifies and strategy business summary, In creating and term that and from customer our our concentration. standpoint, I'm building smooths stream focused a out runway, defensible on cash
of strategy in expect this of able and share to be metrics quarter third year. We our to the the milestones
revenue. our or ended the XX, December the summarize XXXX. million for offset million, million, decrease with and December financial product $XX.X for in to year quarter $X.X fiscal Revenues XX% of $X.X now by $X.X detection over service million $XX.X revenue, increase The $X.X the XXXX XX, a I'll a million million in revenue XXXX. decreased million fourth results in year $XX.X segment reduction were ended
The full therapy decreased or a due to therapy revenue million revenues in for segment revenue. in decrease year XXXX. $X.X primarily $X.X million product decrease million to $X.X XX% was The
million million $X.X $X.X for $X.X segment revenue $X.X offset quarter decreased XXXX revenue. in revenue. revenue down therapy $X.X revenues quarter fourth decrease in The in XX% a increase of with by in revenue, The service The the the $X.X to XXXX. or million product Total due primarily detection revenue to $X.X segment was million to million $X.X of fourth the million was a $X.X product a XXXX. from of million, quarter from XX% million, in decrease therapy fourth decreased million approximately reduction
profit profit, gross fourth for fourth million fourth to the to gross XXXX. in of for in for profit the XXXX compared quarter was XX% reduction million Moving $X.X on quarter as the of the quarter of a compared quarter Gross XX% was XXXX, percentage basis $X.X of to XXXX revenue. reflective of on the fourth
quarter fourth operating in quarter The cost $X.X or expenses million decrease XX% XXXX. decrease were measures cutting for million, was XXXX. fourth XXXX from $X.XX in of Total the implemented million $X.XX a related to of the
million $X.X in margin decrease The This was from same decline to operating decrease gross million as quarter due XXXX. the $X.X loss from million XX December reduced in operating in by a the operating loss to offset in expenses, ended predominantly XXXX period decreased revenues. $X.X in the
a of XXXX. quarter GAAP $X.XX GAAP net year-over-year with primarily of to GAAP operating the compared for million $X.X of reductions. million the loss or loss $X.X the diluted XXXX diluted is for loss fourth share net due or per was decrease This share $X.XX quarter fourth in per per expense share,
of million quarter to million a $X.X $X Non-GAAP mentioned, now end of expenses, the following for share. annualized fourth ahead, net was I $X.X to was $X.XX loss million. Looking XXXX profitability per of reduced XXXX fourth EBITDA to million just projecting are of adjusted or we before the $X.X return of quarter loss as for adjusted the XXXX. the Non-GAAP
as of and and was cash XXXX. of the XXXX, to million company the cash $XX.X compared the XX, from fourth million balance to cash December XX, XXXX used equivalents Moving during cash sheet activities had December at equivalents Cash million. equivalents and $X.X of $XX.X cash quarter of operating
financial would operator turn concludes our call lead This the to Q&A. the presentation. the us of I highlights to now over to like through And back the